Table 3.
Current T-VEC Clinical Trials.
| Cancer Type | NCT Number | Phase | Number of Subjects Enrolled | Intervention |
|---|---|---|---|---|
| Breast Cancer | NCT03802604 | Phase I | 28 (active) | Evaluate the efficacy of T-VEC with atezolizumab in subjects with breast cancer |
| NCT03554044 | Phase I | recruiting | Evaluate the efficacy of T-VEC with established chemotherapy or endocrine therapy in patients with Her2 negative breast cancer | |
| NCT02779855 | Phase I and II | 50 (active) | Evaluate the efficacy of T-VEC with paclitaxel in patients with triple negative breast cancer | |
| Colorectal Cancer | NCT03256344 | Phase I | 36 (completed) | Intrahepatic injection of T-VEC with IV administered atezolizumab in triple negative breast cancer |
| NCT03300544 | Phase I | 3 (active) | T-VEC in combination with 5-fluorouracil, leucovorin, oxaliplatin, capecitabine, and chemoradiation before surgery in treating patients with rectal cancer | |
| Liver Cancer | NCT02509507 | Phase I | 127 (active) | T-VEC injected into liver tumors alone and in combination with systemic pembrolizumab |
| Malignant Pleural Effusion | NCT03597009 | Phase I and II | 1(terminated) | Administration of T-VEC into the intrapleural space of subjects with malignant pleural effusion through a pleurX catheter. |
| Melanoma | NCT03064763 | Phase I | 18 (active) | Administration of T-VEC by intralesional injection into patients with unresectable stage IIIB-IV malignant melanoma |
| NCT03088176 | Phase Ib | 4 (active) | Administration of T-VEC by intralesional injection in conjunction with oral therapy with dabrafenib and trametinib | |
| NCT01740297 | Phase Ib and II | 217 (completed) | Administration of T-VEC in combination with ipilimumab | |
| NCT02366195 | Phase II | 112 (completed) | Dose response of intralesional injection of T-VEC into cutaneous, subcutaneous and nodal lesions. | |
| NCT04068181 | Phase II | 72 (active) | Administration of T-VEC in combination with pembrolizumab in patients with prior anti-PD-1 therapy for unresectable/metastatic melanoma | |
| NCT02211131 | Phase II | 150 (completed) | Administration of T-VEC followed by surgical resection of melanoma | |
| NCT02965716 | Phase II | 47 | Combined T-VEC and pembrolizumab administration in patients with melanoma that progressed on anti-PD1/L1 | |
| NCT02819843 | Phase II | 19 (active) | Administration of T-VEC with or without radiotherapy for cutaneous melanoma, Merkel cell carcinoma or other solid tumors. | |
| NCT03972046 | Phase II | (withdrawn) | Administration of T-VEC in combination with FRAF/MEK inhibitor | |
| NCT02574260 | Phase II | 3 (completed) | Extension protocol for extended use of T-VEC in subjects participating in NCT00289016 | |
| NCT00289016 | Phase II | 50 (completed) | Intratumoral injection of T-VEC in patients with stage IIIc and stage IV malignant melanoma | |
| NCT03842943 | Phase II | 28 (active) | Administration of pre-operative T-VEC injections combined with the neoadjuvant pembrolizumab | |
| NCT02263508 | Phase III | 713 (terminated) | Intratumoral injections of T-VEC and pembrolizumab | |
| NCT01368276 | Phase III | 31 (completed) | Treatment of tumors with GM-CSF and T-VEC-extension protocol of NCT00769704 | |
| NCT00769704 | Phase III | 437 (completed) | Treatment of unresectable stage IIIb and IV melanoma with T-VEC compared to subcutaneous GM-CSF. | |
| Non-CNS Tumors | NCT02756845 | Phase I | 15 (active) | Treatment of children 12-21yo with advanced non-CNS tumors with direct injection of tumors with T-VEC |
| Non-Melanoma Skin Cancer | NCT03458117 | Phase I | 26 (completed) | Intratumoral injection of T-VEC in patients with non-melanoma skin cancer |
| NCT04163952 | Phase I | 5 (active) | IM-delivered T-VEC combined with panitumumab delivered IV to patients with advanced squamous cell carcinoma | |
| NCT03714828 | Phase II | 28 (recruiting) | Intralesional injection of T-VEC in patients with low-risk squamous cell carcinoma. | |
| Other | NCT03747744 | Phase I | 18 (active) | Intratumoral injection of T-VEC followed by injection of CD1c+ myDC to subcutaneous, cutaneous, soft tissue metastases. |
| NCT03555032 | Phase I and II | 15 (completed) | Administration of T-VEC by isolated limb perfusion (ILP) for treatment of melanoma and sarcoma | |
| NCT02014441 | Phase II | 61 (completed) | Intralesional injection of T-VEC in subjects with unresected, stage IIIB to IVM1c melanoma | |
| Pancreatic Cancer | NCT03086642 | Phase I | 9 (active) | Endoscopically delivered T-VEC in patients with pancreas cancer refractory to at least one chemotherapeutic agent |
| NCT00402025 | Phase I | 17 (competed) | Targeted delivery of T-VEC by endoscopic ultrasound in patients with irresectable pancreatic cancer | |
| Peritoneal Malignancies | NCT03663712 | Phase I | 24 (recruiting) | Intraperitoneal T-VEC treatment in patients with peritoneal surface dissemination from gastrointestinal recurrent, platinum-resistance ovarian tumors |
| Sarcoma | NCT02453191 | Phase I and II | 30 (active) | T-VEC treatment combined with radiation therapy in patients with soft tissue sarcoma |
| NCT04065152 | Phase II | 20 (recruiting) | T-VEC treatment of Kaposi sarcoma | |
| NCT03886311 | Phase II | 40 (recruiting) | Treatment of patients with advanced sarcoma with T-VEC, nivolumab and trabectedin | |
| NCT03069378 | Phase II | 60 (recruiting) | Combination therapy of T-VEC and pembrolizumab in patients with sarcoma | |
| NCT02923778 | Phase II | 40 (recruiting) | Combined T-VEC and radiation therapy in localized soft tissue sarcoma | |
| NCT03921073 | Phase II | 5 (active) | Intralesional injections of T-VEC in patients with advanced cutaneous angiosarcoma | |
| Squamous Cell Carcinoma | NCT02626000 | Phase I | 36 (completed) | T-VEC in combination with pembrolizumab in patients with recurrent or metastatic squamous cell carcinoma of the head and neck |